FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1944-1956 May 10, 2007 Number 19 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Baden, L. R. Editorial by Syrjänen, S. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Substantial molecular evidence suggests a role for human papillomavirus (HPV) in the pathogenesis of oropharyngeal squamous-cell carcinoma, but epidemiologic data have been inconsistent.

Methods We performed a hospital-based, case–control study of 100 patients with newly diagnosed oropharyngeal cancer and 200 control patients without cancer to evaluate associations between HPV infection and oropharyngeal cancer. Multivariate logistic-regression models were used for case–control comparisons.

Results A high lifetime number of vaginal-sex partners (26 or more) was associated with oropharyngeal cancer (odds ratio, 3.1; 95% confidence interval [CI], 1.5 to 6.5), as was a high lifetime number of oral-sex partners (6 or more) (odds ratio, 3.4; 95% CI, 1.3 to 8.8). The degree of association increased with the number of vaginal-sex and oral-sex partners (P values for trend, 0.002 and 0.009, respectively). Oropharyngeal cancer was significantly associated with oral HPV type 16 (HPV-16) infection (odds ratio, 14.6; 95% CI, 6.3 to 36.6), oral infection with any of 37 types of HPV (odds ratio, 12.3; 95% CI, 5.4 to 26.4), and seropositivity for the HPV-16 L1 capsid protein (odds ratio, 32.2; 95% CI, 14.6 to 71.3). HPV-16 DNA was detected in 72% (95% CI, 62 to 81) of 100 paraffin-embedded tumor specimens, and 64% of patients with cancer were seropositive for the HPV-16 oncoprotein E6, E7, or both. HPV-16 L1 seropositivity was highly associated with oropharyngeal cancer among subjects with a history of heavy tobacco and alcohol use (odds ratio, 19.4; 95% CI, 3.3 to 113.9) and among those without such a history (odds ratio, 33.6; 95% CI, 13.3 to 84.8). The association was similarly increased among subjects with oral HPV-16 infection, regardless of their tobacco and alcohol use. By contrast, tobacco and alcohol use increased the association with oropharyngeal cancer primarily among subjects without exposure to HPV-16.

Conclusions Oral HPV infection is strongly associated with oropharyngeal cancer among subjects with or without the established risk factors of tobacco and alcohol use.

Source Information

From the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health (G.D.); the Departments of Pediatrics (R.V.), Otolaryngology–Head and Neck Surgery (C.F., W.M.K.), and Pathology (W.H.W.), Johns Hopkins Hospital; and the Division of Viral Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University (M.L.G.) — all in Baltimore; the Division of Cancer Prevention, National Cancer Institute, Bethesda, MD (A.R.K.); and the Infection and Cancer Control Program, German Cancer Research Center, Heidelberg, Germany (M.P.).

Address reprint requests to Dr. Gillison at Johns Hopkins University, Cancer Research Bldg. I, Rm. 3M 54A, 1650 Orleans St., Baltimore, MD 21231, or to gillima{at}jhmi.edu.

Full Text of this Article

Related Letters:

Human Papillomavirus and Oropharyngeal Cancer
Ukpo O. C., Moore E. J., Smith D. I., Williams H., Higgins C. D., Crawford D. H., Braakhuis B. J., Snijders P. J., Leemans C. R., Gillison M. L.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:1156-1158, Sep 13, 2007. Correspondence

This article has been cited by other articles:

• Goldstein, N. E., Genden, E., Morrison, R. S. (2008). Palliative Care for Patients With Head and Neck Cancer: "I Would Like a Quick Return to a Normal Lifestyle". JAMA 299: 1818-1825 [Abstract] [Full Text]  
• Hughes, D S, Powell, N, Fiander, A N (2008). Will vaccination against human papillomavirus prevent eye disease? A review of the evidence. Br. J. Ophthalmol. 92: 460-465 [Abstract] [Full Text]  
• Gillison, M. L., D'Souza, G., Westra, W., Sugar, E., Xiao, W., Begum, S., Viscidi, R. (2008). Distinct Risk Factor Profiles for Human Papillomavirus Type 16-Positive and Human Papillomavirus Type 16-Negative Head and Neck Cancers. JNCI J Natl Cancer Inst 100: 407-420 [Abstract] [Full Text]  
• Sanchez, I. E., Dellarole, M., Gaston, K., de Prat Gay, G. (2008). Comprehensive comparison of the interaction of the E2 master regulator with its cognate target DNA sites in 73 human papillomavirus types by sequence statistics. Nucleic Acids Res 36: 756-769 [Abstract] [Full Text]  
• Chaturvedi, A. K., Engels, E. A., Anderson, W. F., Gillison, M. L. (2008). Incidence Trends for Human Papillomavirus-Related and -Unrelated Oral Squamous Cell Carcinomas in the United States. JCO 26: 612-619 [Abstract] [Full Text]  
• Goon, P, Sonnex, C (2008). Frequently asked questions about genital warts in the genitourinary medicine clinic: an update and review of recent literature. Sex. Transm. Infect. 84: 3-7 [Abstract] [Full Text]  
• Gralow, J., Ozols, R. F., Bajorin, D. F., Cheson, B. D., Sandler, H. M., Winer, E. P., Bonner, J., Demetri, G. D., Curran, W. Jr, Ganz, P. A., Kramer, B. S., Kris, M. G., Markman, M., Mayer, R. J., Raghavan, D., Ramsey, S., Reaman, G. H., Sawaya, R., Schuchter, L. M., Sweetenham, J. W., Vahdat, L. T., Davidson, N. E., Schilsky, R. L., Lichter, A. S. (2008). Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screening A Report From the American Society of Clinical Oncology. JCO 26: 313-325 [Abstract] [Full Text]  
• Ignatius, R. T., Wills, S. M., Nadeau, L., Deperalta-Venturina, M., Weiner, S. (2008). Leptomeningeal Carcinomatosis Due to Squamous Cell Carcinoma of the Uterine Cervix Associated With HPV-45. JCO 26: 154-156 [Full Text]  
• Choong, N., Vokes, E. (2008). Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer. CA Cancer J Clin 58: 32-53 [Abstract] [Full Text]  
• Applebaum, K. M., Furniss, C. S., Zeka, A., Posner, M. R., Smith, J. F., Bryan, J., Eisen, E. A., Peters, E. S., McClean, M. D., Kelsey, K. T. (2007). Lack of Association of Alcohol and Tobacco with HPV16-Associated Head and Neck Cancer. JNCI J Natl Cancer Inst 99: 1801-1810 [Abstract] [Full Text]  
• Friedman, J., Nottingham, L., Duggal, P., Pernas, F. G., Yan, B., Yang, X. P., Chen, Z., Van Waes, C. (2007). Deficient TP53 Expression, Function, and Cisplatin Sensitivity Are Restored by Quinacrine in Head and Neck Cancer. Clin. Cancer Res. 13: 6568-6578 [Abstract] [Full Text]  
• Hoque, A., Parnes, H. L., Stefanek, M. E., Heymach, J. V., Brown, P. H., Lippman, S. M. (2007). Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research. Cancer Res. 67: 8989-8993 [Abstract] [Full Text]  
• Smith, J. L., Campos, S. K., Ozbun, M. A. (2007). Human Papillomavirus Type 31 Uses a Caveolin 1- and Dynamin 2-Mediated Entry Pathway for Infection of Human Keratinocytes. J. Virol. 81: 9922-9931 [Abstract] [Full Text]  
• Ukpo, O. C., Moore, E. J., Smith, D. I., Williams, H., Higgins, C. D., Crawford, D. H., Braakhuis, B. J., Snijders, P. J., Leemans, C. R., Gillison, M. L. (2007). Human Papillomavirus and Oropharyngeal Cancer. NEJM 357: 1156-1158 [Full Text]  
• Glick, M. (2007). The health questionnaire: A continually changing component of practice. Journal of the American Dental Association 138: 932-934 [Full Text]  
• Baden, L. R., Curfman, G. D., Morrissey, S., Drazen, J. M. (2007). Human Papillomavirus Vaccine -- Opportunity and Challenge. NEJM 356: 1990-1991 [Full Text]  
• Syrjanen, S. (2007). Human Papillomaviruses in Head and Neck Carcinomas. NEJM 356: 1993-1995 [Full Text]  
• (2007). HPV-16 and Oropharyngeal Cancer. JWatch Infect. Diseases 2007: 2-2 [Full Text]  
• (2007). HPV-16 and Oropharyngeal Cancers. Journal Watch Dermatology 2007: 2-2 [Full Text]